Skip to Main content Skip to Navigation
Journal articles

Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment.

Abstract : ABSTRACT: BACKGROUND: Friedreich ataxia is a neurological disease originating from an iron-sulfur cluster enzyme deficiency due to impaired iron handling in the mitochondrion, aconitase being particularly affected. As a mean to counteract disease progression, it has been suggested to chelate free mitochondrial iron. Recent years have witnessed a renewed interest in this strategy because of availability of deferiprone, a chelator preferentially targeting mitochondrial iron. METHOD: Control and Friedreich's ataxia patient cultured skin fibroblasts, frataxin-depleted neuroblastoma-derived cells (SK-N-AS) were studied for their response to iron chelation, with a particular attention paid to iron-sensitive aconitase activity. RESULTS: We found that a direct consequence of chelating mitochondrial free iron in various cell systems is a concentration and time dependent loss of aconitase activity. Impairing aconitase activity was shown to precede decreased cell proliferation. CONCLUSION: We conclude that, if chelating excessive mitochondrial iron may be beneficial at some stage of the disease, great attention should be paid to not fully deplete mitochondrial iron store in order to avoid undesirable consequences.
Document type :
Journal articles
Complete list of metadatas
Contributor : Pierre Rustin <>
Submitted on : Monday, June 30, 2008 - 3:31:37 PM
Last modification on : Saturday, March 28, 2020 - 2:08:05 AM
Long-term archiving on: : Monday, October 1, 2012 - 10:36:43 AM


Publisher files allowed on an open archive




Sergio Goncalves, Vincent Paupe, Emmanuel Dassa, Pierre Rustin. Deferiprone targets aconitase: Implication for Friedreich's ataxia treatment.. BMC Neurology, BioMed Central, 2008, 8 (20), ⟨10.1186/1471-2377-8-20⟩. ⟨inserm-00292152⟩



Record views


Files downloads